37148-86-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-trifluoromethyl-phenyl)-1H-imidazole is used as a pharmaceutical intermediate for the synthesis of various medicinal compounds. Its electron-withdrawing properties and unique chemical structure contribute to the development of new drugs for the treatment of diseases and disorders.
Used in Chemical and Biological Research:
4-(4-trifluoromethyl-phenyl)-1H-imidazole is also used as a research tool in chemical and biological research. Its properties and reactivity make it a valuable compound for studying various chemical reactions and biological processes, furthering our understanding of its potential applications in medicine and other fields.

Upstream product

• 383-53-9 2-bromo-1-[4-(trifluoromethyl)phenyl]ethanone 
• 77287-34-4 formamide 
• 186581-53-3 diazomethane 
• 329-15-7 4-trifluoromethyl-phenyl acetyl chloride 

Downstream Products

• 1181214-82-3 4-[1-(4-heptafluoropropyloxyphenyl)-1H-[1,2,4]triazol-3-yl]-phenylamine 
• 1181214-24-3 4-[4-(4-trifluoromethylphenyl)-1H-imidazol-1-yl]-benzonitrile 
• 774522-73-5 3-[5-(4-trifluoromethyl-phenyl)-imidazol-1-ylmethyl]-benzoic acid 
• 218131-42-1 3-[5-(4-trifluoromethyl-phenyl)-imidazol-1-ylmethyl]-benzoic acid methyl ester 
• 218131-40-9 3-[4-(4-trifluoromethyl-phenyl)-imidazol-1-yl]-propionitrile 

Relevant academic research and scientific papers

One-pot synthesis of 2-alkyl-4(5)-aryl-1H-imidazoles from 1-aryl-2-bromoethanones, ammonium carbonate and aliphatic carboxylic acids

A simple and efficient protocol for the preparation of 2-alkyl-4(5)-aryl- 1H-imidazoles starting from α-bromo aryl methyl ketones and aliphatic carboxylic acids in the presence of ammonium carbonate has been developed.

P70 S6 KINASE INHIBITORS

The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.

Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists

An imidazolylpyrimidine was identified in a CXCR2 chemokine receptor antagonist screen and was optimized for potency, in vitro metabolic stability, and oral bioavailability. It was found that subtle structural modification within the series affected the o

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K

An orally bioavailable series of ketoamide-based cathepsin K inhibitors with good pharmacokinetic properties has been identified. Starting from a potent inhibitor endowed with poor drug properties, conformational constraint of the P2-P3 linker and modifications to P1′ elements led to an enhancement in potency, solubility, clearance, and bioavailability. These optimized inhibitors attenuated bone resorption in a rat TPTX hypocalcemic bone resorption model.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.